aBLA Filing Intelligence & Biosimilar Opportunity

Emrelis

Telisotuzumab Vedotin-Tllv

Anticancer

Single-Dose Vial

Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.

Approval Date

14-May-25

Data Exclusivity Expiry

14-May-29

Market Exclusivity Expiry

14-May-37

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

118

2027

246

2028

432

2029

582

2030

705

2031

806

2032

901

Molecule profile

Details & specifications

Molecule

Telisotuzumab Vedotin-Tllv

Innovator

ABBVIE INC

Dosage Form

Single-Dose Vial

Strength

20 mg and 100 mg

Therapeutic Category

Anticancer

Usage

To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high C-Met protein overexpression after prior systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets